U
KITE

UBS’s Kite Pharma, Inc. KITE Stock Holding History

UBS’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$99K Buy
+3,459
New +$85.6K ﹤0.01% 6019

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

UBS's KITE Position: Q3 2014 in Review

UBS opened a new position in Kite Pharma, Inc. (KITE) in Q3 2014: 3,459 shares worth $99K. The stake represents ﹤0.01% of the portfolio and ranks #6019 among its holdings.

62 funds tracked by Wall St. Rank hold KITE as of Q3 2014.

  • UBS held 3,459 shares of Kite Pharma, Inc. worth $99K as of Q3 2014.
  • Kite Pharma, Inc. was a new UBS position in Q3 2014.
  • Kite Pharma, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6019 holding.
  • 62 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.